Disaggregation of Revenue [Table Text Block] |
The following table represents our revenues disaggregated by product line (in thousands):
| | | | | | | | | | | | | | | | | | | | | | | | | Three months ended September 30, | | Nine months ended September 30, | Product line | 2024 | | 2023 | | 2024 | | 2023 | Consumables | $ | 264,875 | | | $ | 242,010 | | | $ | 770,730 | | | $ | 715,108 | | Infusion Systems | 159,769 | | | 148,981 | | | 480,745 | | | 463,836 | | Vital Care | 164,487 | | | 162,320 | | | 500,766 | | | 492,326 | | Total Revenues | $ | 589,131 | | | $ | 553,311 | | | $ | 1,752,241 | | | $ | 1,671,270 | |
For the three and nine months ended September 30, 2024, net sales to Medline made up approximately 18% and 17% of total revenues, respectively. For the three and nine months ended September 30, 2023, net sales to Medline made up approximately 18% and 16% of total revenues, respectively.
The following table represents our revenues disaggregated by geography (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | Three months ended September 30, | | Nine months ended September 30, | Geography | 2024 | | 2023 | | 2024 | | 2023 | United States | $ | 369,515 | | | $ | 355,984 | | | $ | 1,118,810 | | | $ | 1,063,037 | | Europe, the Middle East and Africa | 101,710 | | | 88,014 | | | 295,409 | | | 276,994 | | APAC | 60,288 | | | 59,064 | | | 173,365 | | | 177,719 | | Other Foreign | 57,618 | | | 50,249 | | | 164,657 | | | 153,520 | | Total Revenues | $ | 589,131 | | | $ | 553,311 | | | $ | 1,752,241 | | | $ | 1,671,270 | |
|
Contract with Customer, Asset and Liability [Table Text Block] |
The following table presents the changes in our contract balances for the nine months ended September 30, 2024 and 2023 (in thousands), which is included in accrued liabilities and other long-term liabilities on the condensed consolidated balance sheets: | | | | | | | Contract Liabilities | Beginning balance, January 1, 2024 | $ | 42,177 | | | | Equipment revenue recognized | (41,392) | | Equipment revenue deferred due to implementation | 38,825 | | Software revenue recognized | (23,591) | | Software revenue deferred due to implementation | 24,559 | | Government grant income recognized(1) | (1,551) | | Government grant income deferred | — | | Other deferred revenue | 503 | | Other deferred revenue recognized | (2,562) | | Ending balance, September 30, 2024 | $ | 36,968 | | | | Beginning balance, January 1, 2023 | $ | 45,866 | | | | Equipment revenue recognized | (24,872) | | Equipment revenue deferred due to implementation | 25,620 | | Software revenue recognized | (13,546) | | Software revenue deferred due to implementation | 12,797 | | Government grant income deferred | 944 | | Government grant income recognized(1) | (3,164) | | Other deferred revenue | 1,674 | | Other deferred revenue recognized | (4,748) | | Ending balance, September 30, 2023 | $ | 40,571 | |
|
Deferred Revenue, by Arrangement, Disclosure |
As of September 30, 2024, revenue from remaining performance obligations is as follows:
| | | | | | | | | | | | | Recognition Timing | (in thousands) | < 12 Months | | > 12 Months | Equipment deferred revenue | $ | 14,641 | | | $ | 1,713 | | Software deferred revenue | 10,185 | | | 459 | | Government grant deferred income(1) | 2,064 | | | 7,864 | | Other deferred revenue(2) | 42 | | | — | | Total | $ | 26,932 | | | $ | 10,036 | |
_________________________________ (1) The government grant deferred income is amortized over the life of the related depreciable asset as a reduction to depreciation expense. (2) Other deferred revenue includes pump development programs, purchased training and extended warranty.
|